[go: up one dir, main page]

MX2013010962A - Nuevos derivados de furanona. - Google Patents

Nuevos derivados de furanona.

Info

Publication number
MX2013010962A
MX2013010962A MX2013010962A MX2013010962A MX2013010962A MX 2013010962 A MX2013010962 A MX 2013010962A MX 2013010962 A MX2013010962 A MX 2013010962A MX 2013010962 A MX2013010962 A MX 2013010962A MX 2013010962 A MX2013010962 A MX 2013010962A
Authority
MX
Mexico
Prior art keywords
optionally substituted
hydrogen atom
substituted heterocyclic
furanone derivative
heterocyclic ring
Prior art date
Application number
MX2013010962A
Other languages
English (en)
Other versions
MX344474B (es
Inventor
Takayuki Irie
Ayako Sawa
Maasaki Sawa
Tokiko ASAMI
Yoko Funakoshi
Chika Tanaka
Original Assignee
Carna Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Carna Biosciences Inc filed Critical Carna Biosciences Inc
Publication of MX2013010962A publication Critical patent/MX2013010962A/es
Publication of MX344474B publication Critical patent/MX344474B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se proporciona un nuevo derivado de furanona, y una medicina que incluye el mismo. El derivado de furanona se representa por la fórmula (I): (Ver Formula) en donde A representa -COOR1 o un átomo de hidrógeno; R1 representa un átomo de hidrógeno, un grupo de hidrocarburo opcionalmente sustituido, o un heterociclo opcionalmente sustituido; R2 y R3 son los mismos o diferentes y representan cada uno independientemente un átomo de hidrógeno, un grupo de hidrocarburo opcionalmente sustituido, un grupo fenilo opcionalmente sustituido, un heterociclo opcionalmente sustituido, un anillo fusionado heterocíclico opcionalmente sustituido, o un grupo amino opcionalmente sustituido; o de manera alternativa, R2 y R3, tomados conjuntamente con el átomo de nitrógeno al cual están unidos, pueden formar un heterociclo opcionalmente sustituido o un anillo fusionado heterocíclico opcionalmente sustituido; y R4 representa un átomo de hidrógeno o un átomo de halógeno; con la condición que cuando A representa -COOR1, R2 y P3 no son grupos amino opcionalmente sustituidos al mismo tiempo, y cuando A representa un átomo de hidrógeno, R3 representa un átomo de hidrógeno.
MX2013010962A 2011-03-31 2012-03-30 Nuevos derivados de furanona. MX344474B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011080185 2011-03-31
PCT/JP2012/058636 WO2012133802A1 (ja) 2011-03-31 2012-03-30 新規フラノン誘導体

Publications (2)

Publication Number Publication Date
MX2013010962A true MX2013010962A (es) 2014-04-25
MX344474B MX344474B (es) 2016-12-16

Family

ID=46931496

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013010962A MX344474B (es) 2011-03-31 2012-03-30 Nuevos derivados de furanona.

Country Status (12)

Country Link
US (3) USRE48140E1 (es)
EP (1) EP2692728B1 (es)
JP (3) JP5659356B2 (es)
KR (1) KR101964479B1 (es)
CN (1) CN103459388B (es)
AU (3) AU2012233246B2 (es)
BR (1) BR112013024957A2 (es)
CA (1) CA2830148C (es)
DK (1) DK2692728T3 (es)
ES (1) ES2687450T3 (es)
MX (1) MX344474B (es)
WO (1) WO2012133802A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX344474B (es) 2011-03-31 2016-12-16 Carna Biosciences Inc Nuevos derivados de furanona.
EP3100742B1 (en) * 2014-01-31 2020-05-20 Carna Biosciences Inc. Anticancer agent composition comprising a cdc7 inhibitor and a wee1 inhibitor
CN104744353B (zh) * 2015-03-31 2017-11-24 山东友帮生化科技有限公司 2‑氨基‑3‑碘‑5‑氯吡啶的合成方法
WO2018084266A1 (en) * 2016-11-04 2018-05-11 Carna Biosciences, Inc. Furanone derivates and methods of use thereof
GB201807147D0 (en) 2018-05-01 2018-06-13 Oncologica Uk Ltd Therapeutic combination
US12533353B2 (en) 2018-09-24 2026-01-27 Carna Biosciences, Inc. Methods of treatment of cancer comprising CDC7 inhibitors

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6987113B2 (en) * 1997-06-11 2006-01-17 Sugen, Inc. Tyrosine kinase inhibitors
US6335342B1 (en) * 2000-06-19 2002-01-01 Pharmacia & Upjohn S.P.A. Azaindole derivatives, process for their preparation, and their use as antitumor agents
MXPA05000629A (es) 2002-07-17 2005-04-25 Pharmacia Italia Spa Derivados de pirazol heterobiciclico como inhibidores de cinasa.
US20050101623A1 (en) 2003-07-23 2005-05-12 Pharmacia Corporation Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors
US20050043346A1 (en) 2003-08-08 2005-02-24 Pharmacia Italia S.P.A. Pyridylpyrrole derivatives active as kinase inhibitors
BRPI0413438A (pt) 2003-08-08 2006-10-17 Pharmacia Italia Spa derivados de pirimidilpirrol ativos como inibidores de cinase
FR2876103B1 (fr) 2004-10-01 2008-02-22 Aventis Pharma Sa Nouveaux derives bis-azaindoles, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
CN100569773C (zh) * 2004-10-14 2009-12-16 霍夫曼-拉罗奇有限公司 作为抗癌剂的新型吖吲哚噻唑啉酮
US20060122232A1 (en) * 2004-12-06 2006-06-08 Development Center For Biotechnology 4-Hydroxyfuroic acid derivatives
US7371862B2 (en) * 2005-11-11 2008-05-13 Pfizer Italia S.R.L. Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
US8263604B2 (en) 2006-03-27 2012-09-11 Nerviano Medical Sciences S.R.L. Pyridyl- and pyrimidinyl-substituted pyrrole-, thiophene- and furane-derivatives as kinase inhibitors
FR2907120B1 (fr) * 2006-10-12 2013-01-11 Sanofi Aventis Nouveaux derives imidazolones,leur preparation a titre de medicaments,compositions pharmaceutiques,utilisation comme inhibiteurs de proteines kinases notamment cdc7
WO2008109443A2 (en) 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting cdk2 gene expression and uses thereof
WO2009155052A1 (en) * 2008-05-28 2009-12-23 Wyeth 3-substituted-1h-pyrrolo[2,3-b]pyridine and 3-substituted-1h-pyrrolo[3,2-b]pyridine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
US20100061982A1 (en) 2008-09-10 2010-03-11 Wyeth 3-substituted-1h-indole, 3-substituted-1h-pyrrolo[2,3-b]pyridine and 3-substituted-1h-pyrrolo[3,2-b]pyridine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
WO2011008915A1 (en) 2009-07-15 2011-01-20 Abbott Laboratories Pyrrolopyridine inhibitors of kinases
TW201127384A (en) 2009-11-18 2011-08-16 Nerviano Medical Sciences Srl Therapeutic combination comprising a Cdc7 inhibitor and an antineoplastic agent
EP2588478A1 (en) 2010-06-29 2013-05-08 SBI Biotech Co., Ltd. Azaindole derivative
MX344474B (es) 2011-03-31 2016-12-16 Carna Biosciences Inc Nuevos derivados de furanona.
EP3100742B1 (en) 2014-01-31 2020-05-20 Carna Biosciences Inc. Anticancer agent composition comprising a cdc7 inhibitor and a wee1 inhibitor

Also Published As

Publication number Publication date
AU2017203986A1 (en) 2017-07-06
CN103459388B (zh) 2015-11-25
JP6256927B2 (ja) 2018-01-10
JP2015042663A (ja) 2015-03-05
CN103459388A (zh) 2013-12-18
EP2692728A4 (en) 2014-08-20
AU2019203483A1 (en) 2019-06-06
BR112013024957A2 (pt) 2016-12-20
JPWO2012133802A1 (ja) 2014-07-28
USRE48140E1 (en) 2020-08-04
AU2012233246A1 (en) 2013-10-10
KR20140056164A (ko) 2014-05-09
CA2830148A1 (en) 2012-10-04
CA2830148C (en) 2020-07-28
JP5891576B2 (ja) 2016-03-23
JP2016084363A (ja) 2016-05-19
US20140018533A1 (en) 2014-01-16
DK2692728T3 (en) 2018-10-08
JP5659356B2 (ja) 2015-01-28
USRE46815E1 (en) 2018-05-01
ES2687450T3 (es) 2018-10-25
AU2017203986B2 (en) 2019-02-28
EP2692728A1 (en) 2014-02-05
EP2692728B1 (en) 2018-07-04
US8742113B2 (en) 2014-06-03
KR101964479B1 (ko) 2019-04-01
WO2012133802A1 (ja) 2012-10-04
AU2012233246B2 (en) 2017-03-30
MX344474B (es) 2016-12-16

Similar Documents

Publication Publication Date Title
IN2014MN01897A (es)
PH12014501179B1 (en) New bicyclic dihydroisoquinoline-1-one derivatives
MY169043A (en) New dihydroquinoline-2-one derivatives
MY186165A (en) New bicyclic dihydroquinoline-2-one derivatives
MY169267A (en) New aryl-quinoline derivatives
UA113643C2 (xx) N-цикліламіди як нематоциди
PH12015502232A1 (en) Naphthyridine derivatives useful as alpha-v-beta-6 integrin antagonists
PH12014500813A1 (en) Novel [1,2,3] triazolo [4,5-d] pyrimidine derivatives as agonists of the cannabinoid receptor
MX343225B (es) Nuevos derivados de aril-benzocicloalquil-amida.
MX2015001099A (es) Nuevos derivados biciclicos de piridina.
PH12016502358B1 (en) Novel pyrrolidine compound and application as melanocortin receptor agonist
MX2012008141A (es) Compuestos y metodos.
PH12013502434A1 (en) Substituted pyridopyrazines as novel syk inhibitors
NZ710052A (en) Novel pyrazol derivatives
WO2013076315A3 (en) Substituted n-(tetrazol-5-yl)- and n-(triazol-5-yl)arylcarboxamide compounds and their use as herbicides
PH12014501540A1 (en) 4-(benzoimidazol-2-yl) - thiazole compounds and related aza derivatives
MX349373B (es) Nuevos derivados de pirazina.
MX2013010962A (es) Nuevos derivados de furanona.
GB201305247D0 (en) Amide Compounds
MX2013005753A (es) Nuevos derivados de biaril amida.
PH12015501146A1 (en) Hydantoin derivative
PH12013500657A1 (en) 1,4-oxazepane derivatives
EA201201674A1 (ru) Способы разделения замещенных по атому азота производных (s)-5-алкокси-2-аминотетралина
MX2013013021A (es) Nuevos compuestos de hexahidropirroloimidazolona.
EA201300340A1 (ru) Новые соединения дигидробензоксатиазепина, способ их получения и содержащие их фармацевтические композиции

Legal Events

Date Code Title Description
FG Grant or registration
PD Change of proprietorship

Owner name: CARNA BIOSCIENCES, INC.